03:42 AM EDT, 04/18/2024 (MT Newswires) -- Intra-Cellular Therapies ( ITCI ) said late Wednesday it priced an underwritten public offering of about 6.8 million common shares at $73 per share for expected gross proceeds of $500 million.

The underwriters have been granted a 30-day option to purchase up to approximately 1 million additional shares.

Closing of the offering is expected to occur on April 22, subject to customary conditions.